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ABSTRACT 45 
 46 
The plasma membrane tetraspan molecule MS4A4A is selectively expressed by 47 
macrophage-lineage cells, but its function is unknown. Here we report that MS4A4A was 48 
restricted to murine and human mononuclear phagocytes and was induced during 49 
monocyte-to-macrophage differentiation in the presence of interleukin 4 or 50 
dexamethasone. Human MS4A4A was coexpressed with M2/M2-like molecules in subsets 51 
of normal tissue-resident macrophages, infiltrating macrophages from inflamed synovium, 52 
and tumor-associated macrophages. MS4A4A interacted and co-localized with the β-53 
glucan receptor Dectin-1 in lipid rafts. In response to Dectin-1 ligands, MS4A4A-deficient 54 
macrophages showed defective signaling and defective production of effector molecules. 55 
In experimental models of tumor progression and metastasis, MS4A4A deficiency in 56 
macrophages had no impact on primary tumor growth, but was essential for Dectin-1-57 
mediated activation of macrophages and natural killer (NK) cell-mediated metastasis 58 
control. Thus, MS4A4A is a tetraspan molecule selectively expressed in macrophages 59 
during differentiation and polarization, essential for Dectin-1 dependent activation of NK 60 
cell-mediated resistance to metastasis. 61 
 62 
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INTRODUCTION 65 
 66 
Macrophages are central players in the pathophysiology of infections and cancer, 67 
being capable of adapting to the local microenvironment assuming a range of different 68 
phenotypes. During infections, macrophages sense pathogens through pattern recognition 69 
receptors and by the release of immune mediators orchestrate the activation of 70 
proinflammatory immune responses. This can be mimicked in vitro by the exposure to 71 
bacterial compounds and interferon γ (IFN-γ), which promotes a classical activation of 72 
macrophages (M1), endowed with pro-inflammatory features. At the opposite side of a 73 
spectrum of activation phenotypes, interleukin 4 (IL-4) and other stimuli induce 74 
macrophages to acquire an alternative phenotype (M2)1,2. Macrophages also coordinate 75 
immune responses by complex bidirectional interplay with other immune cells. In tumors, 76 
in particular, tumor-associated macrophages (TAMs) establish a network with tumor and 77 
host cells supporting a protumoral microenvironment3,4. TAMs promote tumor progression 78 
by different means, ranging from stimulation of angiogenesis to suppression of adaptive 79 
immune responses through the triggering of the activity of inhibitory immune checkpoint 80 
molecules, such as PD-L1, PD-L2, and VISTA5. Based on this, targeting TAMs represents 81 
a major therapeutic option under investigation3. Several markers have been reported to 82 
identify specific macrophage subsets as well as distinct macrophage activation profiles6,7, 83 
8. The present study investigated in particular the expression and function of the tetraspan 84 
molecule membrane spanning 4-domains A4A (MS4A4A), which belongs to the 85 
transcription signature of M2-polarized macrophages and TAMs6,9. MS4A4A was 86 
selectively expressed in tissue-resident macrophages, in homeostatic as well as in 87 
inflammatory conditions, and was highly expressed in TAMs, both in humans and mice. 88 
MS4A4A functionally associated with Dectin-1 in macrophage lipid rafts and was required 89 
for the full activation of Syk-dependent signaling pathway and consequent production of 90 
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cytokines and reactive oxygen intermediates upon Dectin-1 engagement. Though 91 
macrophage-selective genetic inactivation of Ms4a4a had no impact on primary 92 
mesenchymal carcinogenesis and transplanted tumor growth, we found that MS4A4A-93 
deficient macrophages were impaired in their ability to support Dectin-1-dependent cross-94 
talk with natural killer (NK) cells, resulting in uncontrolled metastatic spread. 95 
96 
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RESULTS 97 
 98 
MS4A4A expression is restricted to macrophages. 99 
Transcriptomic data from others and us have previously identified MS4A4A as a putative 100 
marker of human macrophages undergoing IL-4-dependent alternative activation6,9. When 101 
investigated at the protein level by flow cytometry, macrophages were the only leukocyte 102 
population scoring positive, while circulating myeloid (polymorphonuclear neutrophils 103 
(PMNs), monocyte subsets, myeloid and plasmacytoid dendritic cells) and lymphoid cells 104 
(NK, NKT, T, B) scored negative (Fig. 1a). Monocyte-derived dendritic cells did not 105 
express MS4A4A (Supplementary Fig. 1a,b) and were also negative for MS4A6A 106 
(Supplementary Fig. 1c,d) and MS4A7 (Supplementary Fig. 1e-f), two other members of 107 
the MS4A family highly expressed on macrophages6. In vitro, MS4A4A expression 108 
progressively increased during macrophage colony-stimulating factor (M-CSF)-dependent 109 
monocyte differentiation to macrophages (Fig. 1b). When regulation of MS4A4A 110 
expression in mature macrophages was investigated, we first confirmed its induction in 111 
alternative macrophages activated by IL-4, but not by other stimuli inducing M2-like 112 
phenotypes such as transforming growth factor-β (TGF-β) and IL-10 (Fig. 1c). We then 113 
identified the glucocorticoid hormone dexamethasone (Dex) as a second potent inducer of 114 
MS4A4A expression, alone or in combination with IL-4 (Fig. 1c,d). MS4A4A transcript 115 
abundance was increased by Dex treatment at 18 h, at which time a significant increase in 116 
MS4A4A protein expression was also detected (Fig. 1e,f). Glucocorticoids were also 117 
demonstrated to act as potent MS4A4A inducers in vivo, as MS4A4A transcript levels were 118 
strongly upregulated in circulating monocytes isolated from Graves’ syndrome patients 119 
upon acute exposure to methylprednisolone (Fig. 1g). Conversely, Dex treatment was 120 
unable to induce expression of MS4A4A, MS4A6A, or MS4A7 in monocyte-derived 121 
dendritic cells (Supplementary Fig. 1). Both in resting macrophages and more prominently 122 
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in macrophages activated by Dex and IL-4 in combination, MS4A4A expression was 123 
significantly enriched in the CD163+ macrophage subset, while its expression did not 124 
correlate with CD36 and CD206 expression (Fig. 1h). 125 
To define MS4A4A expression in tissues, we first interrogated the public gene 126 
expression database RefExA, which indicated expression of the MS4A4A transcript in 127 
several normal human tissues (Supplementary Fig. 2a). Analysis of cell type-specific gene 128 
expression revealed that MS4A4A expression was restricted to macrophages 129 
(Supplementary Fig. 2b). In agreement with those data, immunohistochemical analysis 130 
detected MS4A4A expression in several human tissues, including colon, lung, and skin 131 
(Fig. 2). Also in vivo, combined staining confirmed that MS4A4A expression was restricted 132 
to the CD163+ macrophages (Fig. 1b,e,h). Importantly, lung plasmacytoid dendritic cells 133 
(CD303+; Fig. 1c), colon dendritic cells (CD1c+; Fig. 1f), and skin Langerhans cells 134 
(CD207+; Fig. 1i) did not express MS4A4A. Finally, when MS4A4A expression was 135 
investigated in the synovium of early rheumatoid arthritis (RA) patients, a prototypic 136 
chronic inflammatory condition, MS4A4A resulted again predominantly expressed by a 137 
subset of CD163+ macrophages (Fig. 3a,b) and was not detected in CD3+ T cells, CD20+ B 138 
cells, or CD138+ plasma cells (Fig. 3c) infiltrating the inflamed synovium. Taken together, 139 
these results indicate that both in normal and in chronic inflammatory conditions MS4A4A 140 
expression is restricted to tissue-resident macrophages, where it is upregulated by IL-4 141 
and glucocorticoid hormones. 142 
 143 
MS4A4A is not functionally relevant for protumoral functions of tumor-associated 144 
macrophages. 145 
The gene expression database TCGA also reported the MS4A4A transcript signature in a 146 
large number of human tumors (Supplementary Fig. 3a), though in some cases to a lower 147 
extent as compared to corresponding normal tissues. Consistent with this, 148 
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immunohistochemical analysis detected MS4A4A expression in melanoma, as well as in 149 
colon and lung tumors. Combined analysis confirmed that its expression was restricted to 150 
CD163+ TAMs (Fig. 4a,c,e), in agreement with results obtained on in vitro differentiated 151 
human macrophages and in inflamed synovium. A strong correlation between MS4A4A 152 
and CD163 transcript levels and, to minor extent, other M2/TAM markers, was also evident 153 
in the TCGA cancer dataset (Supplementary Fig. 3b). Importantly, tumor-associated 154 
dendritic cells did not express MS4A4A (Fig. 4b,d,f). 155 
As the absence of a specific antibody prevented us from investigating the 156 
expression of mouse MS4A4A protein, we evaluated Ms4a4a expression at the transcript 157 
level by qPCR. Consistent with results obtained in the human setting, macrophages were 158 
the only leukocyte population present in mouse spleen with detectable Ms4a4a transcripts 159 
(Supplementary Fig. 4a). IL-4 or Dex, alone or in combination, strongly augmented 160 
Ms4a4a expression, while the M1 polarizing treatment IFN-γ and lipopolysaccharide (LPS) 161 
failed to induce its expression (Supplementary Fig. 4b). In line with abundant MS4A4A 162 
expression detected by immunohistochemistry in human TAMs, we detected elevated 163 
levels of the murine Ms4a4a transcripts in murine TAMs isolated from animals bearing 164 
LCC and B16F1 tumors, as well as xenograft tumors of the human kidney cancer cell line 165 
A498 (Fig. 4g). 166 
As Ms4a4a was highly expressed in murine TAMs, we investigated its functional 167 
relevance for carcinogenesis and tumor progression in different tumoral experimental 168 
models. To this purpose, mice with macrophage-selective deletion of Ms4a4a were 169 
generated. Ms4a4a expression was successfully abrogated in bone marrow-derived 170 
macrophages (BMDMs) of Ms4a4afl/flLysCre/+ animals (indicated here as Ms4a4a–/–; 171 
Supplementary Fig. 4c), with no apparent phenotype or impact on the development for any 172 
immune cell subset (Supplementary Fig. 4d). When animals were tested, we found no 173 
difference in appearance, incidence, and growth of primary tumors in mice having 174 
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MS4A4A-competent or -incompetent macrophages, neither in the B16F1 transplanted 175 
tumor model (Fig. 4h) nor in a model of mesenchymal carcinogenesis based on 3-176 
methylcholanthrene (3-MCA) exposure (Fig. 4i,j). We conclude that, though highly 177 
expressed in TAMs, MS4A4A has no functional relevance for their ability to promote 178 
primary tumor growth, at least under the experimental conditions tested. 179 
 180 
MS4A4A colocalizes with Dectin-1 in lipid rafts. 181 
In search for a functional role of MS4A4A in macrophages, we considered the structural 182 
homology of MS4A proteins with tetraspanins, which are known to engage latero-lateral 183 
interactions with other membrane proteins and influence their functional properties10,11. By 184 
performing a split-ubiquitin yeast two-hybrid screening, an approach previously applied to 185 
identify partners of other MS4A members12, we identified membrane proteins interacting 186 
with MS4A4A. These included MS4A4A itself as well as MS4A6A and MS4A7, two other 187 
MS4A family members highly expressed in alternative macrophages6, suggesting that on 188 
the macrophage plasma membrane these three MS4A members may interact among 189 
themselves. We then validated MS4A4A interaction with itself as well as the other two 190 
MS4A proteins in CHO-K1 transfected cells by FLIM-FRET analysis (Fig. 5a–c), which 191 
indicates that these proteins likely organize in clusters on plasma membranes. Conversely, 192 
FLIM-FRET experiments did not reveal interaction of MS4A4A with the tetraspanins CD63 193 
(Förster radius 1.24 ± 0.15 vs 1.27 ± 0.06 for vector- and MS4A4A-transfected cells, 194 
respectively; p > 0.05) and CD9 (Förster radius 1.28 ± 0.06 vs 1.26 ± 0.05 for vector- and 195 
MS4A4A-transfected cells, respectively; p > 0.05). Candidate MS4A4A interactors 196 
emerged from the split-ubiquitin yeast two-hybrid screening also included the membrane 197 
receptor for β-glucan Dectin-1, whose interaction with MS4A4A also was confirmed by 198 
FLIM-FRET analysis (Fig. 5d). Flow cytometry analysis indicated that macrophages had 199 
high co-expression of MS4A4A and Dectin-1, both under resting conditions and upon Dex 200 
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treatment (Supplementary Fig. 5). Confocal microscopy experiments revealed that 201 
MS4A4A and Dectin-1 colocalization was significantly increased by the Dectin-1 agonist 202 
zymosan, which also induced a significant increase in the colocalization index of both 203 
MS4A4A and Dectin-1 with the lipid rafts tracer CT-B (Fig. 5e-h). Super-resolution 204 
stimulated emission depletion (STED) microscopy further confirmed increased 205 
colocalization of MS4A4A and Dectin-1 upon zymosan stimulation, as well as increased 206 
colocalization of both proteins with CT-B (Fig. 5i-k). Interestingly, treatment with the 207 
cholesterol-depleting agent methyl-β-cyclodextrin (MβCD) completely abrogated the 208 
zymosan-induced increase in Dectin-1 colocalization with MS4A4A (Fig. 5i-l). Taken 209 
together, these results indicate that, upon exposure to Dectin-1 agonists, MS4A4A and 210 
Dectin-1 colocalizes in lipid rafts on the macrophage plasma membrane, suggesting a 211 
functional relevance of MS4A4A on Dectin-1 signaling. 212 
 213 
MS4A4A is required for Dectin-1 signalling activity. 214 
We next investigated the role of MS4A4A in Dectin-1 function. Dectin-1 was similarly 215 
expressed on BMDMs generated from Ms4a4a–/– and wild-type mice, and no difference 216 
was observed in the rate of Dectin-1 internalization induced by its agonist zymosan (Fig. 217 
6a). Similarly, binding of zymosan-FITC particles was identical in BMDMs generated from 218 
Ms4a4a–/– and wild-type animals (Fig. 6b). MS4A4A expression was also not relevant for 219 
Dectin-1 internalization and phagocytosis when Aspergillus fumigatus conidia were used 220 
(Fig. 6c). 221 
In order to investigate the relevance of MS4A4A for Dectin-1 signaling, 222 
phosphorylation events for the three main signaling pathways acting downstream Dectin-1 223 
(Syk, p38, and ERK) were assessed in BMDMs generated from Ms4a4a–/– and wild-type 224 
mice. Upon zymosan challenge, only Syk phosphorylation was significantly reduced in 225 
Ms4a4a–/– as compared to wild-type BMDMs (Fig. 6d), while ERK and p38 phosphorylation 226 
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was unaffected (Fig. 6e-f). Similar results were obtained when curdlan and depleted 227 
zymosan, two Dectin-1-specific agonists, were used, but not when BMDMs were 228 
stimulated with phorbol 12-myristate 13-acetate (PMA) (Supplementary Fig. 6a–c). Neither 229 
p38 nor ERK phosphorylation were influenced by MS4A4A expression with any of the 230 
stimuli used (Supplementary Fig. 6d-e). In accordance with reduced Syk phosphorylation, 231 
upon zymosan challenge Ms4a4a–/– BMDMs released less pro-inflammatory cytokines, 232 
including IL-6 and tumor necrosis factor (TNF), and produced less ROS as compared to 233 
wild-type BMDMs (Fig. 6g–i). The same defect was observed when depleted zymosan and 234 
curdlan were used (Supplementary Fig. 6f,g,i,j). Of note, the absence of MS4A4A did not 235 
impact on cytokine production by BMDMs stimulated with TLR agonists, such as LPS (Fig. 236 
6g–h) or Pam3Cys (Supplementary Fig. 6h,k). 237 
Taken together, these results indicate that MS4A4A is dispensable for Dectin-1-238 
mediated microbial recognition and phagocytosis, but is required to support optimal Syk 239 
phosphorylation and production of inflammatory cytokines and ROS following Dectin-1 240 
engagement. 241 
 242 
MS4A4A contributes to Dectin-1-mediated protection against metastasis. 243 
Dectin-1 has recently been shown to allow dendritic cell/macrophage-dependent 244 
recognition of tumor-associated molecular patterns on some tumor cells13. This Dectin-1-245 
mediated recognition pathway was shown to have an impact on the metastatic potential of 246 
the low metastatic B16F1 melanoma cells. Conversely, this pathway had no relevance for 247 
the metastatic potential of the highly metastatic B16F10 melanoma cells, which were found 248 
negative for the appropriate N-glycan structures recognized by Dectin-113. In accordance 249 
with this evidence, we observed a higher binding of wheat germ agglutinin (WGA), which 250 
recognizes N-acetylglucosamine residues, on the surface of B16F1 cells as compared to 251 
B16F10 cells (Fig. 7a). As shown for the pathogen-derived Dectin-1 agonists, the tumor 252 
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B16F1 cells were able to trigger Syk phosphorylation and cytokine production by BMDMs. 253 
Importantly, both Syk phosphorylation and IL-6 secretion induced by B16F1 cells were 254 
reduced in Ms4a4a–/– as compared to wild-type cells (Fig. 7b,c). 255 
Prompted by this observation, we assessed the relevance of Dectin-1 and MS4A4A 256 
expression in macrophages for the metastatic potential in vivo of B16F1 and B16F10 cells. 257 
In agreement with earlier observations13, B16F1 cells showed a significant higher 258 
metastatic potential in Dectin-1-deficient animals (Clec7a-/-) compared to wild-type mice, 259 
whereas no difference was observed in the number of metastasis generated by B16F10 260 
cells (Fig. 7d,e, respectively). Similarly to previous observations on Dectin-1-deficient 261 
animals13, macrophage-specific Ms4a4a deletion had no effect on the metastatic 262 
spreading of B16F10, but resulted in a significant increase in the number of B16F1 263 
metastasis, whose metastatic potential became comparable to that of B16F10 (Fig. 7f,g, 264 
and Supplementary Fig. 7a). Of note, the number of B16F1 metastasis was not further 265 
increased when mice double-deficient for MS4A4A and Dectin-1 (Ms4a4a–/–Clec7a–/–) 266 
were used, consistent with the idea the two molecules cooperate in a common recognition 267 
pathway (Supplementary Fig. 7b). Importantly, the increased B16F1 metastatic spreading 268 
observed in the absence of Dectin-1 or MS4A4A was also evident when N-glycans-269 
depleted B16F1 cells were injected in wild-type animals (Fig. 7h). Similar experiments 270 
were then performed with two colon carcinoma cell lines that exhibit different metastatic 271 
potential. As observed for B16 cells, the low metastatic MC38 cells showed high WGA 272 
binding and an increased number of metastasis when injected in both Clec7a–/– and 273 
Ms4a4a–/– mice as compared to wild-type mice (Supplementary Fig. 8a,b,d). Conversely, 274 
the highly metastatic SL4 cells, which showed lower WGA binding as compared to MC38 275 
(Supplementary Fig. 8a), generated the same number of metastasis in both Clec7a–/– and 276 
Ms4a4a–/– animals compared to wild-type animals (Supplementary Fig. 8c,e). Taken 277 
together, these results suggest that the expression of MS4A4A on macrophages is 278 
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required for Dectin-1-mediated control of metastatic spreading of highly N-glycosylated 279 
tumor cells. 280 
In vitro experiments have identified NK cells as effector cells in B16F1 killing13. 281 
Consistent with this, NK cell depletion by the use of an anti-NK1.1 antibody resulted in a 282 
significant increase in B16F1 lung metastasis and abrogated the difference observed 283 
between Ms4a4a–/– and wild-type animals (Fig. 8a,b). Conversely, NK cell depletion did 284 
not abrogate the difference observed in the number of MC38 liver metastasis 285 
(Supplementary Fig. 8d). As confocal microscopy analysis showed that NK cells and 286 
macrophages were located in close proximity in B16F1 lung metastasis, suggesting a 287 
possible cross-talk between NK cells and macrophages in metastatic lesions 288 
(Supplementary Fig. 7c), we then investigated the role of macrophage MS4A4A in NK cell 289 
activation. Though Ms4a4a deletion had no impact on the abundance of NK cells and 290 
macrophages in the lungs bearing B16F1 metastatic lesions (Fig. 8c for NK cells; 291 
Supplementary Fig. 7d-g for macrophages), macrophage expression of MS4A4A was 292 
required for optimal recognition by NK cells of tumor targets. NK cell cytotoxicity, assessed 293 
in vitro as the frequency of CD107a+ cells in a degranulation assay, was significantly lower 294 
when B16F1 cells were cultured with splenocytes from Ms4a4a–/– mice as compared to the 295 
wild-type counterpart (Fig. 8d). Of note, defective activation of NK cells was not observed 296 
when B16F10 cells were used as targets (Supplementary Fig. 7h). 297 
Previous studies suggested that Dectin-1 triggering by tumor cells induces the 298 
expression on macrophage plasma membrane of calcium homeostasis modulator family 299 
member 6 (CALHM6), also known as IFN regulatory factor 3-dependent NK-activating 300 
molecule (INAM), which in turn promotes NK cell activation leading to tumor cell killing13. 301 
Consistent with this, the induction of Calhm6 expression in BMDMs cocultured with B16F1 302 
cells was defective when Ms4a4a–/– cells were used (Fig. 8e). A similar defect was 303 
observed when Dectin-1 ligands were used, but not when BMDMs were activated using 304 
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LPS (Supplementary Fig. 7i,j,k). The lack of MS4A4A also affected the cytokine profile 305 
induced in BMDMs by tumor cell recognition. While induction of Il12p40 after B16F1 306 
engagement did not require MS4A4A expression on BMDMs (Fig. 8f), Ms4a4a–/– BMDMs 307 
expressed significantly less Il15 and Il18 transcripts as compared to wild-type BMDMs 308 
(Fig. 8g,h respectively). A similar defect was evident when BMDMs were stimulated with 309 
zymosan (Supplementary Fig. 7l). In accordance with this finding, IFN-γ production by NK 310 
cells was significant lower when B16F1 cells were cocultured with Ms4a4a–/– splenocytes 311 
as compared to wild-type littermates (Fig. 8i). Taken together, these results are consistent 312 
with a non-redundant role of MS4A4A expression in macrophages in controlling tumor 313 
metastatization by supporting a Dectin-1-dependent recognition of N-glycans on tumor 314 
cells and triggering NK cell-mediated tumor cell killing. 315 
316 
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DISCUSSION 317 
 318 
MS4A4A is a member of the MS4A family, encoded in a 600 Kb region on 319 
chromosome 11q12-13 in human and chromosome 19 in mouse genome14,15. MS4A4A 320 
has been reported by us and by others as a macrophage-restricted transcript associated 321 
with M2/M2-like polarization, and genome-wide association studies have correlated SNP 322 
variants within the MS4A4A/MS4A6A locus with late onset Alzheimer’s disease and 323 
cutaneous systemic sclerosis16 Recent studies have described MS4A4A as a 324 
chemosensor expressed by necklace sensory neurons17 and as a partner of the receptor 325 
tyrosine kinase KIT in mast cells18, but its function in macrophages is unknown. 326 
MS4A proteins are characterized by a common structural organization based on 327 
four putative highly hydrophobic transmembrane domains, two extracellular loops, and 328 
short cytoplasmic N- and C-terminals, tightly resembling tetraspanins19. Tetraspanins, a 329 
large family of cell-surface proteins with a similar structural organization, are known to 330 
establish homo and heterocomplexes called tetraspanin-enriched microdomains in which 331 
they engage lateral interactions with different partners, influencing their trafficking and 332 
signalling properties11,20,21,22. Of note, some MS4A proteins, including CD20/MS4A1, 333 
FcεR1β/MS4A2, and the highly MS4A4A-related protein MS4A4B, have been shown to 334 
enter oligomeric complexes in lipid rafts, where they interact and influence signalling 335 
properties of associated partners12,23,24. Furthermore, MS4A4A has been reported to 336 
regulate the signalling activity of the receptor tyrosine kinase KIT controlling its endocytic 337 
recycling and degradation pathways by a mechanism that involves colocalization of KIT 338 
with caveolin-1 in lipid rafts in mast cells18. Here we have demonstrated that, after Dectin-1 339 
engagement by zymosan, Dectin-1 and MS4A4A translocate in lipid rafts on macrophage 340 
plasma membrane. Of note, Dectin-1 has already been reported to interact with 341 
tetraspanins, which control its availability on the plasma membrane and the quantity of 342 
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cytokines produced after zymosan engagement25. Finally, we also provided evidence of 343 
MS4A4A association with itself and with MS4A6A and MS4A7, other two members of the 344 
MS4A family with a macrophage-restricted expression pattern, and showed that in the 345 
absence of MS4A4A expression the signalling properties of Dectin-1 are affected. Taken 346 
together, our results suggested that these three MS4A proteins might contribute to the 347 
organization of specific microdomains on the plasma membrane of macrophages where 348 
signalling properties of membrane receptors, including Dectin-1, are regulated. 349 
Dectin-1 is a pattern recognition receptor belonging to the non-classical C-type 350 
lectin receptor family26. Dectin-1 plays a pivotal role in controlling a wide range of fungal 351 
infections, including species of Candida, Aspergillus, Pneumocystis, and Coccidioides26,27. 352 
More recently, a role of Dectin-1 in the resistance to a broader range of microorganisms, in 353 
autoimmunity, and in tumor cell recognition has also been recognized28. The signalling 354 
activity of Dectin-1 after ligand engagement requires clustering into a phagocytic 355 
synapse29 and results in enhanced phagocytosis, respiratory burst activity, and 356 
inflammatory cytokines secretion30,31. The Dectin-1 signalling pathway in macrophages is 357 
still ill defined32,33,34. It has however been demonstrated that Dectin-1 signaling activity in 358 
macrophages is delayed as compared to dendritic cells, and that it leads to both Syk-359 
independent and Syk-dependent signalling pathways, which control phagocytosis and 360 
production of effector molecules (cytokines and ROS), respectively32,35,36,37. Our evidence 361 
that MS4A4A-deficient macrophages show normal phagocytic properties but reduced Syk 362 
phosphorylation and impaired cytokine and ROS production indicates that MS4A4A is 363 
functionally relevant for the Syk-dependent signalling pathway in macrophages. In 364 
macrophages, MS4A4A expression was significantly increased by IL-4 and, intriguingly, 365 
glucocorticoids. In patients with Graves’ disease treated with methylprednisolone, 366 
MS4A4A induction was observed in circulating monocytes, thus providing an in vivo 367 
confirmation of the regulation found in vitro. Glucocorticoid hormones are potent regulators 368 
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of immunity and inflammation and macrophages are a prime target for their action under 369 
physiological and pharmacological conditions38. Glucocorticoid hormones not only 370 
suppress inflammatory cytokines production, but also orchestrate tissue remodeling and 371 
reshape macrophage functions with the induction of anti-inflammatory molecules such as 372 
the IL-1 decoy receptor IL-1R239 and selected chemokines40. Moreover, glucocorticoid 373 
hormones have been suggested to set components of the innate immune system in an 374 
alert mode, priming for immediate/early responses to pathogens38. Given the coupling of 375 
MS4A4A with a microbial sensor, its induction could be a component of this early aspect of 376 
the pathophysiology of glucocorticoid hormones. Irrespective of its significance, monocyte 377 
expression of MS4A4A could serve as a biomarker of the response of mononuclear 378 
phagocytes to these agents. 379 
Macrophages have been shown to promote activation of NK cell anti-tumoral 380 
activities through direct cell-cell contacts or soluble mediators, including IL-15 and IFN-381 
β41,42. In this setting, recent evidence in a melanoma model indicates that macrophage 382 
recognition of tumor cell-associated molecular patterns via Dectin-1 is associated with 383 
reduction of tumor burden and metastatic spreading due to the activation of cytotoxic NK 384 
cells13. NK cells are known to play a major role in resistance against hematologic 385 
neoplasms, while their role in solid tumors is usually considered less relevant43. Recent 386 
results challenge this long held view by showing that inactivation of the NK cell checkpoint 387 
IL-1R8 unleashes NK cell mediated resistance against carcinogenesis at NK cell-rich 388 
anatomical sites, such as the liver and the lung44. In line with this general view, results 389 
reported here indicate that when macrophages are engaged via Dectin-1 with B16F1 390 
melanoma cells, the absence of MS4A4A impairs their ability to upregulate 391 
CALHM6/INAM, secrete IFN-γ inducing cytokines, and trigger NK cell-mediated cytotoxic 392 
response, thus hampering NK cell ability to control tumor metastatization to the lung. 393 
Considering these evidences and the observation that MS4A4A is barely detectable in the 394 
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various subsets of circulating monocytes and induced during their differentiation to 395 
macrophages, we conclude that MS4A4A expression on TAM is likely required to support 396 
the interaction between NK cells and TAM observed in metastatic foci, where this cross-397 
talk activates NK cells-mediated tumor cell killing. MS4A4A therefore does not contribute 398 
to the protumoral functions of TAM infiltrating primary tumors and conversely its 399 
expression in macrophages at metastatic sites is required for appropriate NK cell-mediated 400 
anti-tumoral functions. These results are well in line with previous results by us and others 401 
showing that the organ immunological context is indeed a key determinant of effective 402 
antitumor effector mechanisms45, with divergent impact of immune manipulations on 403 
primary versus metastatic tumors46,47. There is evidence that the tissue contexture 404 
contributes to shaping the microenvironment of tumors originating in different organs4. 405 
Moreover, complex and diverse mechanisms orchestrate the formation of metastatic 406 
niches at sites of secondary localization of tumors48. Accordingly, it has long been known 407 
that immune mechanisms can have divergent impact of primary tumors and metastasis3,47, 408 
as shown here for the MS4A4A-Dectin-1 interaction. Thus, in a therapeutic perspective, 409 
pathways of immune resistance at sites of secondary localization should be taken into 410 
account. 411 
Several studies are ongoing with the aim of targeting TAM as a promising immune 412 
strategy to impact on tumor biology3,49. MS4A4A belongs to the same protein family of 413 
CD20 (also known as MS4A1)14, whose targeting by specific monoclonal antibodies has 414 
proven to be effective for the treatment of hematological and autoimmune disorders50. 415 
Thus, from a translational perspective, our discovery of MS4A4A as a new M2/TAM 416 
marker raises the interesting possibility that it may represent a valid target for TAM 417 
depletion, though the anti-tumoral effect has to be balanced with the negative impact on 418 
metastasis spreading we have shown here. Finally, targeting the MS4A4A/Dectin-1 419 
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interaction may allow fine-tuning of uncontrolled, pathogen-triggered innate immune 420 
responses. 421 
422 
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FIGURE LEGENDS 587 
 588 
Figure 1. MS4A4A expression and its regulation in human macrophages. 589 
a-c) Flow cytometry analysis of MS4A4A surface expression on human leukocyte subsets 590 
(a), monocytes during M-CSF-dependent differentiation to macrophages (b), and 591 
differentiated macrophages treated for 18 h as indicated or not (M0) (c). Results are 592 
shown as mean ± SEM of relative Mean Fluorescence Intensity (MFI; fold on isotype). Two 593 
biologically independent experiments were performed, with each dot representing a 594 
biologically independent sample (a: 3 donors for CD14hi/CD16neg monocytes, 595 
CD14lo/CD16pos monocytes, NK, NKT, T, mDC, and pDC; 4 for CD14dim/CD16pos 596 
monocytes, B, PMN; 8 for macrophages; b: 2 donors for day 7 after M-CSF treatment, 3 597 
for monocytes and day 3 after M-CSF treatment; 4 for day 1 and 5 after M-CSF treatment; 598 
c: 3 donors). Statistical analysis by one-way ANOVA. 599 
d) MS4A4A expression on human macrophages treated with IL-4 plus Dex (Dex+IL-4) or 600 
not (Medium) for 18 h. DAPI staining of nuclei is shown in blue. Immunofluorescence 601 
images are representative of one experiment out of three biologically independent 602 
performed. 603 
e-f) Time-course of MS4A4A mRNA (e) and plasma membrane protein (f) in human 604 
macrophages treated with Dex for the indicated time. Results are shown as mean ± SEM 605 
of fold change (e) or relative MFI (f; fold change on M0). Two biologically independent 606 
experiments were performed (3 donors for e and 5 for f). Statistical analysis by two-tailed 607 
one sample Student’s t test. 608 
g) Expression levels of MS4A4A mRNA in monocytes isolated from three Graves’ 609 
syndrome orbitopathy patients before and 6 h after injection with 1 g methylprednisolone. 610 
Results are shown as fold change on untreated cells (open columns). 611 
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h) Flow cytometry analysis of macrophage plasma membrane expression of MS4A4A and 612 
other indicated M2 markers (CD36, CD163, CD206) in resting conditions (-) or after 613 
exposure for 18 h to IL-4 plus M Dex (+).Two biologically independent experiments were 614 
performed (4 donors). 615 
 616 
Figure 2. Macrophage expression of MS4A4A in human tissues. 617 
MS4A4A expression on formalin fixed paraffin-embedded sections of human colon (a-c), 618 
lung (d-f), and skin (g-i). MS4A4A is visualized in brown (single staining in b-e-h, left and 619 
middle panels). In double-stained sections, MS4A4A expression (brown) was combined 620 
with CD163 (blue) in b-e-h right panels, CD1c (blue) in c, CD303 (blue) in f, and CD207 621 
(blue) in i. Omission of primary antibodies was used as negative control (a-d-g panels). 622 
Magnification: 100X (a-d-f and b-e-h left panels; scale bar: 200 μm), 200X (c-f-i; scale bar: 623 
100 μm) and 400X (b-e-h, middle and right panels; scale bar: 50 μm). One set of images 624 
out of five healthy tissues analyzed is shown. 625 
 626 
Figure 3. MS4A4A expression is restricted to CD163+ macrophages in inflamed 627 
synovium. 628 
a and c) Representative immunofluorescence images of MS4A4A expression on formalin 629 
fixed paraffin-embedded sections of synovial tissue from early RA patients. MS4A4A 630 
staining is visualized in yellow, CD68 in green, CD3/CD20/CD138/CD163 in red. Nuclei 631 
were counterstained with DAPI and are visualized in blue. Matching isotype control 632 
antibodies were used as negative control. Magnification: 15X for upper panels (scale bar: 633 
250 µm), and 40X for lower panels (scale bar: 70 µm). One set of images out of five RA 634 
patients analyzed is shown. 635 
b) Percentage of synovial macrophages (CD68+ cells) from early RA patients positive for 636 
MS4A4A and/or CD163, quantified by immunofluorescence in five RA patients. 637 
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 638 
Figure 4. MS4A4A is expressed in murine TAMs but is dispensable for primary 639 
tumor growth. 640 
a-f) MS4A4A expression on formalin fixed paraffin-embedded sections of human colon 641 
adenocarcinoma (a-b), lung adenocarcinoma (c-d), and melanoma (e-f). MS4A4A is 642 
visualized in brown (single staining in a-c-e, left and middle panels). In double-stained 643 
sections, MS4A4A expression (brown) was combined with CD163 (blue) in a-c-e right 644 
panels, CD1c (blue) in b, CD303 (blue) in d, and CD207 (blue) in f. Magnification: 100X in 645 
a-c-e left panels (scale bar: 200 μm), 200X in b-d-f panels (scale bar: 100 μm), and 400X 646 
in a-c-e middle and right panels (scale bar: 50 μm). One set of images out of five cancer 647 
tissues analyzed is shown. 648 
g) Expression levels of the MS4A4A mRNA in murine TAM isolated from B16F1 tumors, 649 
Lewis lung carcinoma (LLC) tumors, and human renal cancer cell A498 tumor xenografts. 650 
Data are normalized to actin and expressed as mean ± SEM of MS4A4A relative 651 
expression in TAMs compared to corresponding PECs, used as control. Results pooled 652 
data (4 mice per group) from one representative experiment out of three run in triplicate for 653 
A498 model and from one experiment (3 mice per group) for LLC and B16F1 models. 654 
h) Tumor growth curve in Ms4a4a-/- (open symbol) and wild-type (closed symbol) mice 655 
upon s.c. injection of B16F1 melanoma cells. Results are shown as mean ± SEM. Two 656 
biologically independent experiments were performed (11 mice). No statistical difference at 657 
any time point by two-tailed unpaired Student’s t test. 658 
i-j) Tumor volume (i) and incidence (j) of 3-methylcholanthrene-induced fibrosarcoma in 659 
Ms4a4a-/- (open symbol) and wild-type (closed symbol) mice. Results are shown as mean 660 
± SEM. Two biologically independent experiments were performed (16 mice). No statistical 661 
difference at any time point by two-tailed unpaired Student’s t test. 662 
 663 
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Figure 5. MS4A4A and Dectin-1 associate in lipid rafts after zymosan engagement. 664 
a-d) FLIM-FRET analysis of eGFP mean fluorescence lifetime in CHO-K1 cells expressing 665 
eGFP-MS4A4A alone (V) or in combination with mCherry-MS4A4A (6 for V and 7 for 666 
MS4A4A), mCherry-MS4A6A (6 for V and 4 for MS4A6A), mCherry-MS4A7 (7 for V and 6 667 
for MS4A7), and mCherry-Dectin-1 (4 for V and 8 for Dectin-1). FRET efficiency (E) and 668 
Förster radius (R) are indicated. Results are shown as mean ± SEM. 669 
e-h) Colocalization of MS4A4A and Dectin-1 in lipid rafts (stained with cholera toxin; CT-B) 670 
in human macrophages treated with 100 μg/ml zymosan. Panel e reports the kinetic of 671 
colocalization of MS4A4A and Dectin-1, panels f and g the kinetics of localization of 672 
MS4A4A and Dectin-1 in lipid rafts, respectively. Results are shown as mean ± SEM of the 673 
colocalization index (Manders coefficient) in 20÷78 cells from three donors analyzed. Error 674 
bars are included in symbols. Statistical analysis in comparison with time 0 was performed 675 
by one-way ANOVA. Images referring to the 30 min time point are shown in panel h, with 676 
nuclei counterstained with DAPI visualised in white. Scale bars: 10 μm. 677 
i-l) STED analysis of MS4A4A and Dectin-1 in lipid rafts (stained with CT-B) in human 678 
macrophages treated (+) or not (-) for 15 min with 100 μg/ml zymosan alone or in 679 
combination with 5 mM MβCD. Panel i shows images from one experiment representative 680 
of two analyzed. Panels j to l report the colocalization rate (%) of MS4A4A in lipid rafts, 681 
Dectin-1 in lipid rafts, and MS4A4A and Dectin-1, respectively. Results are shown as 682 
mean ± SEM of the colocalization rate in 20÷33 cells from 2 donors analyzed. Scale bars: 683 
5 μm. Statistical analysis by two-tailed unpaired (Mann-Whitney) Student’s t test (j and k) 684 
and one-way ANOVA (l). 685 
 686 
Figure 6. MS4A4A is required for Dectin-1 signalling. 687 
Dectin-1 expression and function in BMDMs from wild-type (closed symbol) and Ms4a4a-/- 688 
(open symbol) mice. 689 
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a) Dectin-1 surface expression upon stimulation with 100 μg/ml zymosan (solid line) or 100 690 
ng/ml LPS (dashed line). Results are shown as relative MFI (fold on isotype) mean ± SEM. 691 
Five biologically independent experiments were performed (time 0: 15 wild-type and 25 692 
Ms4a4a-/- mice; 5 min: 11 wild-type and 20 Ms4a4a-/- mice; 15 min: 4 wild-type and 5 693 
Ms4a4a-/- mice; 30 min: 4 wild-type and 3 Ms4a4a-/- mice; 30 min with LPS: 6 wild-type 694 
and 5 Ms4a4a-/- mice). 695 
b) Binding of zymosan-FITC. Results are shown as MFI mean ± SEM (time 0, 5, and 15 696 
min: 6 wild-type and 6 Ms4a4a-/- mice; 30 min: 4 wild-type and 4 Ms4a4a-/- mice). 697 
c) Phagocytosis of Aspergillus fumigatus conidia-FITC. Results are shown as mean ± SEM 698 
of percentage (left y-axis, solid lines) and relative MFI (fold on untreated; right y-axis, 699 
dotted lines) of FITC+ cells gated on F4/80+ cells. Three biologically independent 700 
experiments were performed. At all time points, 6 wild-type and 8 Ms4a4a-/- mice. 701 
d-f) Phosphorylation of Syk (d), ERK (e), and p38 (f) after stimulation with 100 μg/ml 702 
zymosan. Results are shown as relative MFI (fold on untreated) mean ± SEM. Five 703 
biologically independent experiments for d (time 5: 4 wild-type and 5 Ms4a4a-/- mice; time 704 
15: 8 wild-type and 12 Ms4a4a-/- mice), three for e (time 5: 4 wild-type and 7 Ms4a4a-/- 705 
mice; time 15: 4 wild-type and 5 Ms4a4a-/- mice), four for f (time 5: 4 wild-type and 4 706 
Ms4a4a-/- mice; time 15: 4 wild-type and 8 Ms4a4a-/- mice). Statistical analysis by two-707 
tailed unpaired (Mann-Whitney) Student’s t test. 708 
g-h) Secretion of IL-6 (g) and TNF (h) after stimulation for 6 h with 100 μg/ml zymosan or 709 
100 ng/ml LPS. Cytokine levels in untreated cells were below detection limit. Results are 710 
shown as mean ± SEM. Four biologically independent experiments were performed (g: 7 711 
wild-type and 7 Ms4a4a-/- mice for zymosan; 6 wild-type and 7 Ms4a4a-/- mice for LPS; h: 7 712 
wild-type and 6 Ms4a4a-/- mice for zymosan, 7 wild-type and 8 Ms4a4a-/- mice for LPS). 713 
Statistical analysis by two-tailed unpaired (Mann-Whitney) Student’s t test. 714 
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i) ROS production after stimulation with 100 μg/ml zymosan. Results are shown as MFI 715 
mean ± SEM (6 wild-type and 6 Ms4a4a-/- mice). Statistical analysis by two-tailed unpaired 716 
Student’s t test. 717 
 718 
Figure 7. MS4A4A regulates Dectin-1 recognition and control of B16F1 metastasis 719 
a) Flow cytometry analysis of WGA binding on B16F1 and B16F10 cells. Results are 720 
shown as representative dot plot (left) and mean ± SEM of relative MFI (fold on unstained; 721 
right). Six biologically independent experiments were performed (10 independent 722 
samples). Statistical analysis by two-tailed unpaired (Mann-Whitney) Student’s t test. 723 
b) Syk phosphorylation in BMDMs from Ms4a4a-/- (open symbol) and wild-type (closed 724 
symbol) mice primed for 18 h with 10 ng/ml GM-CSF and cocultured at 1:1 ratio with 725 
apoptotic B16F1 cells. Results are shown as relative MFI (fold on unstained) mean ± SEM. 726 
Three biologically independent experiments were performed (11 wild-type and 6 Ms4a4a-/- 727 
mice). Statistical analysis by two-tailed unpaired (Mann-Whitney) Student’s t test. 728 
c) Cytokine secretion by BMDMs from Ms4a4a-/- (open symbol) and wild-type (closed 729 
symbol) mice primed for 18 h with 10 ng/ml GM-CSF and cocultured with B16F1 cells for 6 730 
h. Cytokine levels in untreated cells were below detection limit. Results are shown as 731 
mean ± SEM. Two biologically independent experiments were performed (6 wild-type and 732 
6 Ms4a4a-/- mice). Statistical analysis by two-tailed unpaired (Mann-Whitney) Student’s t 733 
test. 734 
d-e) Number of metastatic foci in lungs from Clec7a-/- (open symbol) and wild-type (WT, 735 
closed symbol) mice upon i.v. injection of B16F1 (d) or B16F10 (e) cells. Results are 736 
shown as mean ± SEM. Three biologically independent experiments for B16F1 cells (9 737 
wild-type and 16 Clec7a-/- mice), one for B16F10 cells (7 wild-type and 6 Clec7a-/- mice). 738 
Statistical analysis by two-tailed unpaired (Mann-Whitney) Student’s t test. 739 
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f-g) Number of metastatic foci in lungs from Ms4a4a-/- (open symbol) and wild-type (WT, 740 
closed symbol) mice upon i.v. injection of B16F1 (f) or B16F10 (g) cells. Results are shown 741 
as mean ± SEM. Five biologically independent experiments for B16F1 cells (23 wild-type 742 
and 26 Ms4a4a-/- mice), three for B16F10 cells (12 wild-type and 15 Ms4a4a-/- mice). 743 
Statistical analysis by two-tailed unpaired (Mann-Whitney) Student’s t test. 744 
h) Number of metastatic foci in lungs from wild-type mice upon i.v. injection of B16F1 745 
treated for 1 h with 25 U/ml N-glycosidase F (N-glyc, open symbol) or buffer (NT, closed 746 
symbol). Results are expressed as mean ± SEM. Two biologically independent 747 
experiments were performed (12 mice for NT, 11 for N-glyc). Statistical analysis by two-748 
tailed unpaired (Mann-Whitney) Student’s test. 749 
 750 
Figure 8. Expression of MS4A4A in macrophages is required for NK-mediated 751 
Dectin-1-triggered protection against metastasis. 752 
a-b) Representative images (a) and number (b) of lung metastasis in Ms4a4a-/- (open 753 
symbol) and wild-type (closed symbol) mice injected i.v. with B16F1 cells upon NK cell 754 
depletion by anti-NK1.1 treatment. Results are shown as mean ± SEM. Two biologically 755 
independent experiments were performed. Statistical analysis by one-way ANOVA and 756 
two-tailed unpaired Student’s t test. 757 
c) NK cell infiltrating the lungs of Ms4a4a-/- (open symbol) and wild-type (WT, closed 758 
symbol) mice injected i.v. with B16F1 cells. Results are shown as mean ± SEM of absolute 759 
numbers (n) of Live/CD45+/CD3-/NK1.1+ cells. Three biologically independent experiments 760 
were performed (9 wild-type and 6 Ms4a4a-/- mice). Statistical analysis by two-tailed 761 
unpaired Student’s t test. 762 
d) Degranulation of NK cells after engagement with B16F1 cells in the presence of 763 
splenocytes from Ms4a4a-/- (open symbol) and wild-type (WT, closed symbol) mice. 764 
Results are shown as mean ± SEM of percentage of CD107a+ NK cells gated on 765 
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Live/CD45+/CD3-/NK1.1+ splenocytes. Two biologically independent experiments were 766 
performed (4 wild-type and 5 Ms4a4a-/- mice). Statistical analysis by two tailed unpaired 767 
(Mann-Whitney) Student’s t test. 768 
e-h) Expression levels of Calhm6 (e), Il12p40 (f), Il15 (g), and Il18 (h) mRNA in Ms4a4a-/- 769 
(open symbol) and wild-type (WT, closed symbol) BMDMs primed with 10 ng/ml GM-CSF 770 
cocultured for 24 h with B16F1 apoptotic cells. Results are shown as mean ± SEM of fold 771 
of induction. Two biologically independent experiments were performed (f: 5 wild-type and 772 
8 Ms4a4a-/- mice; g: 5 wild-type and 8 Ms4a4a-/- mice; h: 4 wild-type and 8 Ms4a4a-/- mice; 773 
i: 4 wild-type and 4 Ms4a4a-/- mice). Statistical analysis by two-tailed unpaired Student’s t 774 
test. 775 
i) IFN-γ production by NK cells after engagement with B16F1 cells in the presence of 776 
splenocytes from Ms4a4a-/- (open symbol) and wild-type (WT, closed symbol) mice. 777 
Results are shown as mean ± SEM of percentage of IFN-γ+ NK cells gated on 778 
Live/CD45+/CD3-/NK1.1+ splenocytes. Two biologically independent experiments were 779 
performed (5 wild-type and 6 Ms4a4a-/- mice). Statistical analysis by two tailed unpaired 780 
(Mann-Whitney) Student’s t test. 781 
782 
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METHODS 783 
 784 
Cells. 785 
Human peripheral blood mononuclear cells were isolated from buffy coats of healthy 786 
donors and monocytes were obtained by serial centrifugation as described6 and approved 787 
by the institutional Ethical Committee of the Humanitas Clinical and Research Center. 788 
Monoctes were treated for 7 days with 50 ng/ml recombinant human (rh) GM-CSF 789 
(Miltenyi Biotech) plus 40 ng/ml rhIL-4 (Peprotech) to obtain dendritic cells, and to 100 790 
ng/ml rhM-CSF (R&D Systems) to obtain macrophages. Macrophages were activated in 791 
vitro by 18 h incubation with either 100 ng/ml 055:B5 LPS (Sigma-Aldrich) plus 20 ng/ml 792 
rhIFN-γ (Peprotech), 20 ng/ml rhIL-10 (Miltenyi Biotech), 10 ng/ml rhTGF-β (Miltenyi 793 
Biotech), 10-6 M dexamethasone (Dex; Sigma-Aldrich), 20 ng/ml rhIL-4, or 10-6 M Dex plus 794 
20 ng/ml IL-4. Murine bone marrow-derived macrophages (BMDMs) were generated by 6 795 
days of culture with 20 ng/ml recombinant murine (rm) M-CSF (Miltenyi Biotech) and were 796 
cultured for 18 h with 100 ng/ml LPS plus 20 ng/ml rmIFN-γ (R&D Systems) or 20 ng/ml 797 
rmIL-4 (R&D Systems). TAMs were isolated from s.c. B16F1 (0.1 × 106) or Lewis lung 798 
carcinoma (LLC; 1 × 106) tumors into C57BL/6J (Charles River Laboratories) or A498 799 
human renal tumor cells (1 × 106) grown in NOD/scid/IL-2R-γnull mice (NOD.Cg-800 
PrkdcscidIl2rgtm1Wjl/SzJ; Jackson Laboratory). After mice were sacrificed (day 14 for LLC 801 
tumors, day 18 for A498 tumors, day 20 for B16F1 tumors), tumors were harvested and 802 
disaggregated. Peritoneal exudate macrophages (PECs) were collected by peritoneal 803 
lavage. Tumor suspension cells and PECs were stained for F4/80 and CD11b and 804 
F4/80+/CD11b+ TAMs and PECs were sorted using an Influx flow sorter (BD Bioscience) 805 
and immediately lysed for RNA extraction. B16F1 and B16F10 cells were cultured in RPMI 806 
1640, 10% FBS, 1% L-glutamine, 1% penicillin/streptomycin, 1% HEPES (Lonza). B16F1 807 
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cells were induced to apoptosis by 5 min heat-shock at 65°C followed by 5 min on ice. 808 
MC38 cells were cultured in Dulbecco's modified Eagle medium (DMEM; Lonza), 10% 809 
FBS, 1% L-glutamine, 1% penicillin/streptomycin, 1% sodium pyruvate, 1% non-essential 810 
amino acids (Lonza). SL4 cells were cultured in DMEM:F12 (1:1) medium (Lonza), 10% 811 
FBS, 1% L-glutamine, 1% penicillin/streptomycin. Chinese hamster ovary (CHO-K1) cells 812 
were grown in DMEM, 10% FBS, 100 U/ml penicillin/streptomycin, and 25 mM HEPES pH 813 
7.2 (Gibco). Transfectants were obtained by lipofection with Lipofectamine 2000 according 814 
to manufacturer's instructions, and selected with 650 μg/ml G418 (Invitrogen). 815 
 816 
Patients’ samples. 817 
Monocytes from patients with active severe Graves orbitopathy were collected before and 818 
6 h after the first i.v. infusion of 1 g methylprednisolone. A signed informed consent for 819 
blood/serum collection and storage and for its use for research purposes was obtained by 820 
the Endocrinology Unit, Fondazione IRCCS Ca’ Granda Policlinico. In agreement with the 821 
institutional policy, the Ethical Committee approval was not required, as patients did not 822 
undergo tests or therapies other than those routinely proposed for their specific disease. 823 
Rheumatoid arthritis (RA) synovium samples were retrieved from early (<12 months 824 
symptoms) patients fulfilling the ACR/EULAR 2010 criteria51 for RA diagnosis, recruited 825 
into the Pathobiology of Early Arthritis Cohort (PEAC; http://www.peac-826 
mrc.mds.qmul.ac.uk/) at Bart’s Health NHS Trust in London. After obtaining written 827 
informed consent, patients underwent an ultrasound-guided needle synovial biopsy of the 828 
most inflamed accessible joint52. Synovial tissue samples were immediately fixed in 4% 829 
formaldehyde (Merck) and subsequently paraffin-embedded. The study was approved by 830 
the institutional Ethical Committee (No. 05/Q0703/198). Histological analysis of normal and 831 
tumoral tissue samples was performed on material obtained from the Surgical Pathology 832 
Unit, ASST-Spedali Civili in Brescia. Experiments performed on archival material were 833 
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approved by the institutional Ethical Committee (WV-Immunocancer 2014 to WV, IRB 834 
code NP906). When requested, an informed consent was obtained from all participants. 835 
 836 
Immunohistochemical and immunofluorescence analysis. 837 
MS4A4A expression was analyzed on 4-μm formalin-fixed paraffin-embedded sections of 838 
normal tissues (skin, lung, colon) and corresponding neoplastic samples (five melanomas, 839 
five lung adenocarcinomas, five colon adenocarcinomas) by staining with anti human 840 
MS4A4A (rabbit polyclonal, dilution 1:4.000; Sigma-Aldrich) and revealing using Novolink 841 
Polymer (Leica Biosystems) as secondary reagent. The chromogen reaction was 842 
developed using diaminobenzidine. For double immunostains, MS4A4A was combined 843 
with CD1c (clone OTI2F4; Abcam), CD163 (clone 10D6; Thermo Fisher Scientific), CD207 844 
(clone 12D6; Vector Laboratories), and CD303 (clone 124B3.13; Dendritics). The second 845 
antibody reactivity was detected using a Mach 4 alkaline phosphatase system with Ferangi 846 
Blue (Biocare Medical) as chromogen. Slides were counterstained with hematoxylin. 847 
Omission of primary antibody was also performed as control staining. Immunostained 848 
sections were photographed using the DP73 Olympus digital camera mounted on the 849 
Olympus BX60 microscope and analyzed by the acquisition software CellSens Standard. 850 
Images were then processed using Adobe Photoshop Cs4 Portable. MS4A4A expression 851 
on inflamed synovium was performed on 3-μm formalin-fixed paraffin embedded sections 852 
obtained from five patients by multiplex immunofluorescence staining using a tyramide 853 
signal amplification protocol and an anti-MS4A4A rabbit polyclonal anti human antibody 854 
(dilution 1:2000; Sigma-Aldrich) in combination with CD68 (mouse anti human IgG1, clone 855 
KP1; Dako), CD163 (mouse anti human IgG1, clone 10D6; Leica Biosystems), CD3 856 
(mouse anti human IgG1, clone F7.2.38; Dako), CD20 (mouse anti human IgG2a, clone 857 
L26; Dako), and CD138 (mouse anti human IgG1, clone MI15; Dako). Matching isotypes 858 
were used as controls. Nuclei were counterstained with 4’,6-diamidino-2’-phenylindole 859 
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(DAPI, 300 nM; Invitrogen) and mounted with ProLong Antifade Mountant (Thermo Fisher 860 
Scientific). Sections were imaged with the digital slide scanner Nanozoomer S60 861 
(Hamamatsu Photonics). The quantification of CD68/MS4A4A/CD163+ cells was 862 
performed using the cell count plugin of the Image J software. TAMs and NK cells 863 
infiltrating experimental metastasis were analyzed on frozen sections (10 μm thick) 864 
obtained from tissue blocks of B16F1 metastasis-bearing lungs. Sections were thawed and 865 
fixed with 4% PFA for 5 min, washed and incubated for 15 min in PBS supplemented with 866 
0.05% Tween-20, 2% BSA, 5% donkey serum (Sigma-Aldrich), and incubated for 1 h with 867 
purified polyclonal goat anti mouse NKp46 (R&D System), rat anti mouse F4/80 868 
(Serotech), and rabbit anti mouse Ki-67 (Cell Signalling). After extensively wash, sections 869 
were incubated for 1 h with Alexa Fluor (488, 568, 647)-conjugated species-specific cross-870 
adsorbed detection antibodies (Molecular Probes). Nuclei were stained using DAPI. 871 
Sections were mounted with 20 μl FluorSave reagent (Calbiochem). Fluorescent high-872 
resolution images were acquired with a Leica SP8 STED 3X confocal microscope (Leica 873 
HC PL APO 60X/1.40 oil STED white objective system) and analyzed by LAS-X software. 874 
 875 
Animal colonies. 876 
Wild-type C57BL/6J mice were obtained by Charles River Laboratories (Calco, Italy). Mice 877 
with macrophage-specific Ms4a4a inactivation in C57BL/6J background were achieved 878 
breading mice carrying floxed Ms4a4a alleles (Ms4a4afl/fl; Ozgene) with mice expressing 879 
Cre under the control of the promoter of the Lys gene, encoding for the myeloid-restricted 880 
lysozyme M protein (LysCre/+; B6.129P2-Lyz2tm1(cre)Ifo/J from Jackson Laboratory). 881 
Ms4a4afl/flLysCre/+ mice (here indicated as Ms4a4a–/–) were born in Mendelian ratios, 882 
reproduced normally, and did not show significant differences in body weight compared to 883 
control floxed littermates (Ms4a4afl/flLys+/+, here used as wild-type animals). Ms4a4a–/– 884 
mice were co-housed with littermates in individually ventilated cages in a specific 885 
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pathogen-free/viral antibody-free animal facility at Humanitas Clinical and Research 886 
Center. Mice in C57BL/6J background with Dectin-1 inactivation (Clec7a–/–; B6.129S6-887 
Clec7atm1Gdb/J) were obtained by Jackson Laboratory. To obtain double-deficient mice 888 
(here indicated as Ms4a4a–/–Clec7a–/–), Clec7a–/– mice were bred with 889 
Ms4a4afl/fl/ubiquitinCCre/+ animals (B6.CgTg(UBC-cre/ERT2)1Ejb/2J from Jackson Laboratory). 890 
Animals were housed in ventilated cages in a specific pathogen-free/viral antibody-free 891 
animal facility at Humanitas Clinical and Research Center. Experiments were performed 892 
using sex- and age-matched mice. 893 
 894 
Experimental models. 895 
The 3-methylcholanthrene (3-MCA)-induced tumor model was performed with 100 μg 3-896 
MCA as previously described53. In the melanoma B16F1 model, tumor dimension was 897 
monitored in mice s.c. injected with 0.1 × 106 B16F1 cells as previously described13. Lung 898 
metastasis were analyzed in the lungs 10 days after i.v. injection with 0.3 × 106 B16F1 or 899 
B16F10 cells and 14 days after i.v. injection with 0.3 × 106 SL4 cells. To visualize 900 
metastasis, lungs from mice injected with SL4 were fixed and stained over night with 901 
Bouin’s Solution (Histoline). Liver metastasis were analyzed 14 days after i.s. injection with 902 
0.25 × 106 MC38 cells. For NK cell depletion in the melanoma model, mice were i.p. 903 
injected with 200 μg anti-NK1.1 (BioXcell) or its isotype control 3 days before and 100 μg 904 
anti-NK1.1 or isotype control 3 and 7 days after B16F1 cells injection and metastasis were 905 
evaluated at day 10. For NK cell depletion in the colon carcinoma model, mice were i.p. 906 
injected with 200 μg anti-NK1.1 (BioXcell) or its isotype control 5 and 3 days before and 3 907 
and 7 and 10 days after MC38 cells injection and metastasis were evaluated at day 12. 908 
Animal procedures were reviewed and approved by the institutional Ethical Committee at 909 
Humanitas Clinical and Research Center and were in accordance with national (D.L. N. 910 
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116, G.U. suppl. 40, 18-2-1992 and N. 26, G.U. 4-3-2014) and international laws and 911 
policies (EEC Council Directive 2010/63/EU, OJ L 276/33 22-9-2010; National Institutes of 912 
Health Guide for the Care and Use of Laboratory Animals, US National Research Council, 913 
2011). The study was approved by the Italian Ministry of Health (approvals n. 89/2013-B 914 
issued on the 8/4/2013, 6B2B3.N.ERY issued on 06/12/2017, and 949/2018-PR issued on 915 
the 20/12/2018). 916 
 917 
Split-ubiquitin assay. 918 
The split-ubiquitin assay was performed as previously described12. Briefly, a split-ubiquitin 919 
NubG-X library, derived from monocyte-derived human macrophages treated with 10-6 M 920 
Dex, was directionally cloned into the prey vector pBT3-N and the bait protein MS4A4A 921 
cDNA was cloned into the bait vector pBT3-STE, in which the LexA-VP16-Cub cassette is 922 
fused to the N-terminus. The yeast strain NMY51 (MATa his3-200 trp1–901 leu2–3,112 923 
ade2 LYS2::(lexAop)4-HIS3 ura3::(lexAop)8-LacZ ade2::(lexAop)8-ADE2 GAL4) was 924 
transformed using standard procedures . Transformants were grown on selective medium 925 
lacking leucine, tryptophan, histidine and adenine, with addition of 20 mM 3-amino-1,2,4-926 
triazole. Positive clones were sequenced by colony PCR (pPR3N-FOR: 5′-927 
GTCGAAAATTCAAGACAAGG-3′; pPR3N-REV: 5′-AAGCGTGACATAACTAATTAC-3′). 928 
Library plasmids were isolated from positive clones and retransformed into NMY51 to test 929 
bait dependency. Prey sequences activating the histidine and adenine reporters in the 930 
presence of MS4A4A and not the empty pBT3-STE vector were considered as potential 931 
MS4A4A interactors. 932 
 933 
Flow cytometry. 934 
For direct multi-color flow cytometry (FACS Canto II and LRS Fortessa; BD Bioscience), 935 
cells were incubated for 30 min at 4°C with directly conjugated anti-human or anti-mouse 936 
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protein antibodies (Supplementary Tables 1 and 2, respectively, Life Science Reporting 937 
Summary) and their appropriate isotype controls. Live/dead cell discrimination was 938 
performed staining with the Zombie Aqua Fixable Viability Kit (BioLegend). For MS4A6A 939 
and MS4A7 surface staining, purified MS4A6A (Abnova) and MS4A7 (Novusbio) 940 
antibodies were used as primary antibodies and anti human IgG-Alexa Fluor 488 941 
(Invitrogen) as secondary antibody. Wheat germ agglutinin Alexa Fluor 594-conjugated 942 
(WGA; ThermoFisher) was used to detect N-acetylglucosamine residues on the surface of 943 
tumor cells. To block Fc receptors, a purified anti mouse CD16/CD32 (BioLegend) was 944 
used. For intracellular staining, cells were permebilized and fixed using the 945 
FoxP3/Transcription Factor Staining Buffer Set (eBioscience). Phosphoproteins were 946 
detected as previously described29 using the anti-phospho-Syk-Tyr525/526 antibody (Cell 947 
Signalling) and the anti-phospo-p38-Thr180/Tyr182 antibody (Cell Signalling) as primary 948 
antibodies and an anti rabbit IgG Alexa Fluor 647 as secondary antibody (Invitrogen) or 949 
the directly conjugated anti-phospho-ERK Alexa Fluor 647 antibody (BD Pharmigen), 950 
according to protocols recommended by the manufacturers. To analyze immune cell 951 
infiltration, lungs were incubated for 1 h at 37°C in 1% DNAse I in HBSS supplemented 952 
with 1 mg/ml collagenase D (Roche) and then for 10 min in 5 mM EDTA on ice. The cell 953 
suspension was passed through a 70 μm filter, red cells were lysed with ACK (Lonza), and 954 
then cells were stained and analyzed by flow cytometry. Data were analyzed with FACS 955 
Diva (BD) and Flow Jo (Treestar) software. Gating strategies are reported in 956 
Supplementary Note. 957 
 958 
Imaging analysis. 959 
Freshly isolated human monocytes were differentiated to macrophages directly on 14-mm 960 
diameter cover glasses (Menzel-Gläser) in 24-well plates and treated as described above. 961 
Cells were fixed with 4% PFA (Euromedex). For intracellular staining, cells were 962 
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permeabilized with 0.1% Triton X-100 (Sigma-Aldrich), 2% BSA (Biosera), 5% goat serum 963 
(Dako) in PBS. Cells were then incubated for 18 h with a purified mouse anti human 964 
MS4A4A MoAb (R&D System) and a purified goat anti human Dectin-1 polyclonal (R&D 965 
System) and then for 1 h with Alexa Fluor (488, 647)-conjugated species-specific cross 966 
adsorbed detection antibodies (Molecular Probes). Nuclei were stained using DAPI. Lipid 967 
rafts were stained with the Vybrant Lipid Raft Labeling Kit, based on the cholera toxin 968 
subunit B (CT-B) labeled with the red-fluorescent Alexa Fluor 594 dye (Molecular Probes), 969 
following the manufacturer protocol. High-resolution images (1024 × 1024 pixels) were 970 
acquired with an Olympus Fluoview FV1000 laser scanning confocal microscope with 60X 971 
(N.A. 1.4) plan-apochromat oil immersion objective (Olympus) and analyzed with ImageJ 972 
software (NIH). Quantitative colocalization and statistical analysis were performed with 973 
Imaris Coloc 4.2 (Bitplane AG) software and FV1000 1.6 colocalization software 974 
(Olympus) and ImageJ Coloc2 plugin. Representative images were smoothed with a 975 
Gaussian filter and upscaled with bicubic interpolation (ImageJ). For STED microscopy, 976 
human macrophages were stained with purified mouse anti human MS4A4A monoclonal 977 
Ab (R&D System) and a purified goat anti human Dectin-1 polyclonal (R&D System) and 978 
then for 1 h with Alexa Fluor (568, 647)-conjugated species-specific cross-adsorbed 979 
detection antibodies (Molecular Probes). Lipid rafts were stained with the Vybrant Lipid 980 
Raft Labeling Kit, based on the CT-B labeled with the green-fluorescent Alexa Fluor 488 981 
324 dye (Molecular Probes), following the manufacturer protocol. Mowiol was used as 982 
mounting medium. Alexa Fluor 488, 568 and 647 were excited with a 400 Hz white light 983 
laser tuned at 485/493, 561/569 and 635/643 nm, respectively, and emission was 984 
collected at 505-550, 580-620, and 650-700 nm, respectively. A gating between 0.4 to 7 ns 985 
was applied to avoid collection of reflection and autofluorescence and sequential 986 
acquisition was applied to avoid fluorescence overlap. The 775 nm CW-depletion laser 987 
(30% of power; ≈90 mW) was used for Alexa Fluor 488, 568 and 647 excitations. STED 988 
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analysis was performed on ROI corresponding to the traced freehand area of the image of 989 
a single cell (3-5 ROIs per image) and xyz images (1928 × 1928 px; px size, 0.05 μm; vx 990 
size, 0.2 μm) were acquired in a z-stack (30-40 images; 0.2 μm slice) with a Leica SP8 991 
STED 3X confocal microscope system adopting a Leica HC PL APO 100x/1.40 oil STED 992 
white objective at 706-929 mAU. CW-STED and gated CW-STED were applied to Alexa 993 
Fluor 488 and Alexa Fluor 568 and 647, respectively. A linear background subtraction was 994 
applied to all z-stack STED images. The colocalization rate was measured with the LASX 995 
software after a maximum intensity projection of the non-deconvolved images. Collected 996 
images were deconvolved with Huygens Professional software. To evaluate the interaction 997 
between MS4A4A and its putative partners, we investigated by Fluorescence Lifetime 998 
Imaging Microscopy (FLIM) the Fluorescence Resonance Energy Transfer (FRET) from an 999 
excited MS4A4A-eGFP donor molecule to ground state proximal acceptor molecules 1000 
chimerized to the fluorescent protein mCherry54. To this purpose, eGFP-MS4A4A and 1001 
mCherry chimerized candidate partners were cotransfected in 2 × 105 CHO-K1 cells 1002 
seeded onto poly-L-lysine treated coverslips, cells were fixed, irradiated with a 830 nm 1003 
light to excite the donor, and imaged using a TriM Scope II two photon laser scanning 1004 
microscope (LaVision Biotec) equipped with a 60X water immersion lens (LUMFL60x; 1005 
Olympus). Light was separated using a IR700 long pass filter and detected with the FLIM 1006 
X16 TCSPC module 350 (LaVision Biotec). FLIM data were fitted with single exponential 1007 
and background correction using Imspector Pro (LaVision Biotech). FRET efficiency (E) 1008 
and Förster radius (R), which express the distance between the molecules, are reported. 1009 
 1010 
Gene expression analysis. 1011 
For real-time PCR assay (qPCR), cells were lysed with QIAzol Reagent (Qiagen) and total 1012 
RNA was extracted using miRNeasy mini kit (Qiagen). RNA was converted in cDNA using 1013 
the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) and quantification 1014 
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of the transcripts reported in Supplementary Table 3 was performed following the 1015 
recommended protocols for SYBR Green Master Mix (Applied Biosystems). Results were 1016 
normalized on human GAPDH or murine Gapdh. qPCR was performed with the ViiA™ 7 1017 
Real-Time PCR System (Applied Biosystems). To determine MS4A4A gene expression 1018 
levels in different human tissues and cells lines and in different cancer types, the 1019 
Laboratory for Systems Biology and Medicine RefExA database 1020 
(http://sbmdb.genome.rcast.u-tokyo.ac.jp/refexa/main_search.jsp) and the Cancer 1021 
Genome Atlas database (TCGA; https://doi.org/10.7908/C11G0KM9) through the 1022 
Firebrowse repository (http://firebrowse.org/) were used. Gene expression levels as rsem 1023 
values were downloaded and distribution boxplots were performed using the ggplot2 R 1024 
package version 2.2.1. Correlation between MS4A4A and TAM markers transcripts were 1025 
performed using the ‘rcorr’ function implemented in Hmisc R package version 4.0.3 1026 
adopting the Pearson’s correlation method. Significant correlations (p < 0.05) were plotted 1027 
using the NMF R package version 0.20.6. Genes with a not significant correlation show a 1028 
coefficient equal to zero. Mentioned source data are provided in Supplementary Fig. 3. 1029 
 1030 
NK cell functional assays. 1031 
NK cell degranulation was investigated by CD107a surface expression, as previously 1032 
reported42. Briefly, splenocytes isolated from Ms4a4a–/– and wild-type mice were treated 1033 
for 18 h with 100 ng/ml rmIL-2 and co-cultured for 4 h with B16F1 or B16F10 cells (E:T 1034 
ratio 12:1). Percentage of CD107a+ NK cells (Live/CD45+/CD3–/NK1.1+) was analyzed by 1035 
flow cytometry. IFN-γ production was investigated on splenocytes isolated from Ms4a4a–/– 1036 
and wild-type mice treated for 12 h with 50 ng/ml rmIL-2 and co-cultured for 4 h with 1037 
B16F1 and additional 2 h with Golgi plug (BD Pharmingen). Percentage of IFN-γ+ NK cells 1038 
(Live/CD45+/CD3–/NK1.1+) was analyzed by flow cytometry. 1039 
 1040 
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Macrophage functional assays. 1041 
To study Dectin-1 functional activities, BMDMs were primed for 18 h with 10 ng/ml GM-1042 
CSF and treated with 100 μg/ml zymosan (InvivoGen), 100 μg/ml depleted zymosan 1043 
(InvivoGen), 100 μg/ml curdlan (Wako Chemicals), 100 ng/ml LPS, 100 ng/ml PMA 1044 
(Sigma-Aldrich), 100 ng/ml Pam3Cys (Enzo Life Science), 20 μg/ml fluorescein-conjugated 1045 
zymosan bioparticles (Molecular Probes), or 5 × 106 Aspergillus fumigatus conidia-FITC. 1046 
To deplete lipid rafts, macrophages were treated for 15 min with 100 μg/ml zymosan alone 1047 
or in combination with 5 mM methyl-β-cyclodextrin (MβCD; Sigma-Aldrich). ROS 1048 
production was investigated using the CellRox Deep Red reagent (Life Technologies) 1049 
according to the manufacturer’s instructions. Live-cell widefield microscopy was performed 1050 
monitoring fluorescence at 350ex/461em (Hoechst) and 640ex/665em (CellROX) with a 1051 
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Statistical analysis. 1055 
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